Key Spec Table
|Species Reactivity||Key Applications||Host||Format||Antibody Type|
|H||IP, WB||M||Purified||Monoclonal Antibody|
|Description||Anti-Bcl-2 Antibody, clone AW604|
|Presentation||0.1M Tris-glycine, pH 7.4, 0.15M NaCl, 0.05% sodium azide before the addition of glycerol to 30%|
|Application||This Anti-Bcl-2 Antibody, clone AW604 is validated for use in IP, WB for the detection of Bcl-2.|
|Safety Information according to GHS|
|Storage and Shipping Information|
|Storage Conditions||2 years at -20°C|
|Material Size||200 µg|
|Reference overview||Pub Med ID|
|Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked.|
Yang, J, et al.
Science, 275: 1129-32 (1997) 1997
Bcl-2 is an integral membrane protein located mainly on the outer membrane of mitochondria. Overexpression of Bcl-2 prevents cells from undergoing apoptosis in response to a variety of stimuli. Cytosolic cytochrome c is necessary for the initiation of the apoptotic program, suggesting a possible connection between Bcl-2 and cytochrome c, which is normally located in the mitochondrial intermembrane space. Cells undergoing apoptosis were found to have an elevation of cytochrome c in the cytosol and a corresponding decrease in the mitochondria. Overexpression of Bcl-2 prevented the efflux of cytochrome c from the mitochondria and the initiation of apoptosis. Thus, one possible role of Bcl-2 in prevention of apoptosis is to block cytochrome c release from mitochondria.
|Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes|
Krajewski, S, et al
Cancer Res, 53:4701-14 (1993) 1993
|Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin|
Reed, J C, et al
Cancer Res, 51:6529-38 (1991) 1991
|Programmed cell death: apoptosis and oncogenesis.|
Williams, G T
Cell, 65: 1097-8 (1991) 1991
|Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation.|
Pezzella, F, et al.
Am. J. Pathol., 137: 225-32 (1990) 1990
It has been reported previously that the bcl-2 protooncogene protein is detectable in neoplastic cells from cases of human lymphoma in which the 14;18 chromosomal translocation is present, but not in lymphomas that lack this chromosomal rearrangement or in normal lymphoid tissue. In the present study we confirmed, by immunohistologic labeling with polyclonal and monoclonal antibodies, that bcl-2 protein is strongly expressed in many cases of follicular lymphoma and that these neoplastic follicles differ clearly from their nonmalignant counterpart (reactive germinal centres) in which bcl-2 protein is undetectable. However we also found bcl-2 protein in normal T- and B-lymphoid cells and in a variety of lymphoproliferative disorders in which the 14;18 translocation is not present. It is therefore concluded that expression of bcl-2 protein is not a specific marker for lymphomas bearing the 14;18 chromosomal translocation and that the observations of other investigators may have reflected the inadequate sensitivity of their staining procedure.